Semaglutide vs Tirzepatide: What To Ask Your Clinic

Semaglutide and tirzepatide are both injectable medications used in weight management and metabolic health contexts, but they differ in their mechanism of action, clinical evidence, and availability across different markets.

Semaglutide is a GLP-1 receptor agonist that works by mimicking the action of a single hormone involved in appetite regulation and blood sugar control. Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors, a more recent approach that has shown strong outcomes in clinical trials.

In terms of evidence, both drugs have been studied in large randomised controlled trials. Tirzepatide trials have reported higher average weight loss percentages in some studies, but these results reflect averages across trial populations and individual outcomes vary considerably based on factors including adherence, lifestyle, dosing, and underlying health status.

Availability differs by country and indication. Semaglutide has been available for longer and has broader regulatory approval across more markets. Tirzepatide is newer and availability through licensed clinic pathways may be more limited in some regions.

Neither drug should be chosen based on headline trial numbers alone. The right choice depends on individual health profile, medical history, contraindications, and the recommendation of a licensed clinician following proper assessment. Both require ongoing monitoring and should be used as part of a broader lifestyle programme.

This guide is informational and does not constitute medical advice. Use Peptide Clinic Finder to compare clinics offering these treatments and send direct enquiries to providers with structured, supervised programmes.